ViGenCell Inc. Logo

ViGenCell Inc.

Developing T-cell immune therapies to treat cancer and other incurable diseases.

308080 | KO

Overview

Corporate Details

ISIN(s):
KR7308080001
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산로9길 66 더리즌밸리 지식산업센터(가산동), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ViGenCell Inc. is a biotechnology company specializing in the research and development of immune cell therapies. The company develops novel treatments for cancers and other incurable diseases, aiming to prolong life expectancy and enhance patient quality of life. Its core technology includes ViTier, a proprietary T-cell therapy platform that employs antigen-specific killer T cells to target and eliminate pathogens or tumor cells. Founded in 2013 as the first subsidiary of the Catholic University Technology Holdings, ViGenCell leverages clinically validated research to advance its therapeutic pipeline.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등거래계획보고서
Korean 40.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-04-30 00:00
Regulatory News Service
기타경영사항(자율공시) (iPSC(유도만능줄기세포) 유래 NK세포치료제 공동개발계약 체결)
Korean 6.8 KB
2025-04-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-04-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-03-28 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 12.6 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 33.6 KB
2025-03-27 00:00
Board/Management Information
대표이사변경
Korean 10.6 KB
2025-03-19 00:00
Audit Report / Information
감사보고서제출
Korean 25.3 KB
2025-03-19 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 395.3 KB
2025-03-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-03-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 90.2 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 818.4 KB
2025-03-11 00:00
Share Issue/Capital Change
주식매수선택권행사
Korean 17.9 KB

Automate Your Workflow. Get a real-time feed of all ViGenCell Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ViGenCell Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ViGenCell Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America
CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France
ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea
471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan
7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan
4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.